The invention relates a method for the injectable delivery of a therapeutic agent into fish embryos, in particular, when the fish embryos are in the one-cell to the eyed egg stage of development.
All previous methods developed for vaccinating teleost fish have used teleost fish that are either in post-larval/juvenile, or in adult life stages. In fact, the accepted knowledge regarding the teleost immune system, is that fish could not be vaccinated at the embryo or larval stage due, not only to their small size, but also because they could not develop specific antibodies and hence, a protective immune response against pathogens until significantly later life stages, (see Vadstein (1997). Aquaculture 155; 401-417). Quoting Almeida et al., “Moreover, vaccination is not possible in the case of fish larvae, which generally are most susceptible to disease, because it is practically unfeasible to handle these small animals and also because it is believed that fish larvae do not have the ability to develop specific immunity.” (Almeida et al., (2009). Phage therapy and photodynamic therapy: Low environmental impact approaches to inactivate microorganisms in fish farming plants. Marine Drugs 7; 268-313). “Yet, in other species, the major disease problems may appear in the larval or fry stages, before the animal is large enough to be vaccinated or have even developed a functional immune system.” (See, Muktar et al., (2016), quoting Bowser P R (1999), Diseases of Fish. Cornell University, Ithaca, N.Y., pp: 18-25). However, the detection of antibodies in teleost fish can occur as early as two days post-fertilization.
Current therapeutic agent delivery methods such as injection into post-larval/juvenile or in adult fish, bath exposure and feed additives are not effective in preventing or treating disease in the early life stages of fish, when it is most economical and efficacious to administer. Existing methods result in wasted vaccine product(s) or therapeutic agent and often result in highly variable or suboptimal efficacy within the intended treatment population.
The most significant obstacle to effective prophylaxis or treatment of infectious diseases in early life stage fish is not the availability of vaccine agents, immunogenic potential, or processing of the vaccine agent, but a method of delivery. A convenient and cost-effective method to deliver therapeutic agents to fish is needed. The delivery of therapeutic agents is problematic due to inefficiency in administering the therapeutic agents and variable efficacy of vaccines. In addition, for vaccination to be optimally effective it must occur early in fish development before fish are exposed to pathogens.
At least partially based on the fact that antibodies can be detected in teleost fish as early as two days post-fertilization, the inventor reasoned that teleost fish embryos could be immunized with therapeutic agents by the injection of therapeutic agents into the embryo yolk sac. In addition, injection into the embryo yolk sac, combined with the use of carriers, would allow for a continued, controlled release and processing of therapeutic agents. For these reasons, the inventor developed a method of immunizing embryos post fertilization that are at the one-cell to eyed egg stage, by injecting the embryo yolk sac microspheres associated with a specific antigen (
After 1 month, 10 treated (injected with a carrier associated with KLH or Mycobacterium marinum protein antigen) and 10 control fish (injected with carrier with no antigen) were humanely euthanized and whole fish protein was isolated from two fish per tube by adding fish to 1 ml of G biosciences protein lysis buffer and protease inhibitors in a 2 ml tube containing sterile 11 mm diameter zirconia/silica beads and subjected to two minutes bead beating (Mini-Beadbeater, Biospec Products) to homogenize the samples and release total protein. All of the isolated protein within each group was pooled and used to detect antibodies specific to KLH or Mycobacterium marinum proteins. For detection of antibodies to KLH, 2 ug of KLH and BSA were run on a 3-8% tris acetate gel (except for 4 month experiment was run on 4-12% gel) for 40 min and transferred to PVDF membrane for 90 min. For detection of antibodies to M. marinum proteins, 40 ug of total protein and 2 ug of BSA were run on a 3-12% Tris Acetate gel for 30 min and transferred to PVDF membrane for 1 hour. Each membrane was blocked for 2 hours in 5% BSA/PBS at RT. Eighty ug of total pooled fish protein was added to 10 ml of 5% BSA/PBS and incubated with the membrane overnight at 4° C. The membrane was washed 3 times, 5 minutes each time, with 200 ml TPBS. Anti-IgM and Anti-IgZ antibodies (AnaSpec, Inc., AS_55789S) specific to zebrafish, were each labeled with HRP (Innova lightning link kit) and incubated with the membrane in solution to detect the presence of fish IgM or IgZ produced by the host fish against KLH or M. marinum proteins. After a 2-hour incubation, the membrane was washed 4× in 200 ul TPBS for 10 min each followed by addition of HRP detection reagent DAB. As evidenced by
As evident from
The result of the inventor's research is that the inventor has found a way to effectively deliver protective or prophylactic therapeutic agents to fish embryos as a way to prevent and treat disease in fish utilizing injection into a fish embryo that is superior to other current therapeutic agent delivery methods. Once vaccinated, fish embryos effectively develop an immune response to the pathogen as they mature. The disclosed method is cost-effective, environmentally friendly, uses FDA approved carrier materials, is efficacious with a high margin of safety, and provides for closely controlled dosing.
The present disclosure reveals a method for the delivery of a therapeutic agent into a fish embryo in the one-cell to eyed egg stage of development.
To prevent disease-related morbidity and mortality by the method of injecting a therapeutic agent into fish embryos as early as 1-hour post fertilization, when the embryos are in the one-cell to the eyed egg stage of development, wherein the injection can be direct or with the use of microspheres as carriers of therapeutic agents. Once vaccinated or treated, fish embryos can effectively moderate their response to therapeutic agents as they mature. The most significant obstacle to effective prophylaxis or treatment of infectious diseases in early life stage fish is not the availability of vaccine agents and therapeutants, immunogenic potential or processing of the vaccine agent, but a method of delivery.
The inventor has developed method of therapeutically treating or vaccinating fish embryos as early as 1-hour post fertilization, when the embryos are in the one-cell to the eyed egg stage of development, by either directly injecting the therapeutic agent or antigen, or by utilizing injectable microspheres as a delivery platform to carry therapeutic agents or antigens, wherein the developed method is not only superior to other current therapeutic agent or vaccine delivery methods, but is effective for fish embryos. The disclosed method is cost-effective, environmentally friendly, uses FDA approved carrier materials, is efficacious with a high margin of safety, and provides for closely controlled dosing.
The present disclosure reveals a method of vaccinating fish embryos with a therapeutic agent 1, wherein said vaccination takes place after fertilization and in particular within the one-cell to eyed egg stage of development comprising, not necessarily in sequential order, the following steps:
Selecting an appropriate therapeutic agent 2.
Obtaining embryo water 3.
Obtaining an injection chamber, into which an embryo will be placed 4 to immobilize the embryo, wherein said injection chamber is designed to hold a fish egg specific to the type of fish to be injected, from the size of a flying fish (Tobiko) fish egg to a whale shark fish egg.
During this step, it is possible to create an injection chamber, by way of example but not limited to, a first layer of gel created and allowed to solidify, followed by the application of a second layer of gel and a mold placed in the liquid so that once the mold is removed an injection chamber is created. Said gel is created from a substance such as but not limited to agarose. Once the injection chamber is created the injection chamber is filled with embryo water.
Loading an injection technique with a therapeutic agent 5.
Obtaining an embryo that will receive the therapeutic agent 6.
Placing the embryo into the injection chamber 7.
Assuring proper stage of development of the embryo 8.
Puncturing the embryo with the needle to inject the therapeutic agent into the embryo yolk sac 9.
Allowing the embryo to further develop 10.
The disclosure may also comprise an additional step that involves the preparation of a carrier 10.
|Vadstein (1997). Aquaculture 155: 401-417.|
|Almeida et al., (2009), “phage therapy and photodynamic therapy: Low environmental impact approaches to inactivate microorganisms in fish farming plants” Marine Drugs 7: 268-313.|
|Muktar et al., (2016), quoting Bowser PR (1999), Diseases of Fish. Cornell University, Ithica, New York, pp. 18-25.|
|Chen P.C.Y., Zhou s., Lu Z. et al (2015), Int. J. Control Autom. Syst. 13: 1233.|
|Spaink H.P., Cui C., Wiweger M.I. et al, Methods (2013) 62(3): 246-254.|
|Wang W, Liu C, Gelinas D, Ciruna B, Sun Y (2007) PLoS One 2(9): e862.|
|Hoffman et al. (1972), “Covalent Binding of Biomolecules to RAdiation-Grafted Hydrogels on Inert Polymer Surfaces,” Trans. Am. Soc. Artif. Intern. Organs, 18, 10-18.|
|Monoclonal Antibodies in Fish Immunology: Identification, Ontogeny and Activity of T- and B-Lymphocytes, Scapigliati et al. Aquaculture 1999; 172:3-28.|
|Fish Immune System. A Crossroads between Innate and Adaptive Responses, Tort et al. Immunologia 2003; 22(3): 277-286.|
|The Astonishing Diversity of Ig Classes and B cell Repertoires in Teleost Fish, Fillatreau et al. Front Immunol Feb. 2013; 4(28):1-14.|
|Discovery of a Unique Ig Heavy-Chain Isotype (IgT) in Rainbow Trout: Implications for a Distinctive B cell Developmental Pathway in Teleost Fish, Hansen et al. PNAS May 10, 2005; 102(19): 6919-6924.|
|Recent Findings on the Structure and Function of Teleost IgT Zhang et al. Fish Shellfish Immunol Nov. 2011; 31(5): 627-634.|
|T cell Diversity and TcR Repertoires in Teleost Fish, Castro et al. Fish & Shellfish Immunology 2011; 31:644-654 I.|
|B Cells in Teleost Fish Act as Pivotal Initiating APCs in Priming Adaptive Immunity: An Evolutionary Perspective on the Origin of the B-1 Cell Subset and B7 Molecules, Zhu et al. J Immunol 2014; 192:2699-2714.|
|Muktar et al., (2016), quoting Bowser PR (1999), Diseases of Fish, Cornell University, Ithaca, New York, pp. 18-25.|
|Wang W, Liu X, Gelinas D, Ciruna B, Sun Y (2007) PLoS One 2(9): e862.|
|20180237742 A1||Aug 2018||US|